Aerie Pharmaceuticals announced the commencement of patient dosing in a Phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion. Safety and efficacy will be evaluated at six months.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.